DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE Drug Patent Profile

Which patents cover Dutasteride And Tamsulosin Hydrochloride, and what generic alternatives are available?

Dutasteride And Tamsulosin Hydrochloride is a drug marketed by Actavis Labs Fl Inc, Aurobindo Pharma, Ph Health, and Zydus Pharms. and is included in four NDAs.

The generic ingredient in DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE is dutasteride; tamsulosin hydrochloride. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dutasteride; tamsulosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dutasteride And Tamsulosin Hydrochloride

A generic version of DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE was approved as dutasteride; tamsulosin hydrochloride by PH HEALTH on February 26^th, 2014.

Summary for DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

US Patents:	0
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	23
Patent Applications:	22
DailyMed Link:	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
EMS	PHASE3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A
Beth Israel Deaconess Medical Center	N/A

See all DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE clinical trials

Pharmacology for DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

Drug Class	5-alpha Reductase Inhibitor alpha-Adrenergic Blocker
Mechanism of Action	5-alpha Reductase Inhibitors Adrenergic alpha-Antagonists

US Patents and Regulatory Information for DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	202975-001	Nov 20, 2015		DISCN	No	No
Zydus Pharms	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	207769-001	May 24, 2018	AB	RX	No	Yes
Aurobindo Pharma	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	213300-001	Jul 18, 2024	AB	RX	No	No

Market Dynamics and Financial Trajectory for Dutasteride and Tamsulosin Hydrochloride

Last updated: February 28, 2026

What drives the market for Dutasteride and Tamsulosin Hydrochloride?

The combination therapy of Dutasteride and Tamsulosin Hydrochloride targets benign prostatic hyperplasia (BPH). The global BPH market was valued at approximately USD 4.5 billion in 2022, with an expected compound annual growth rate (CAGR) of 4.5% from 2023 to 2030. The combination therapy's market share increases driven by factors such as aging populations, rising prevalence of BPH, and advances in drug formulations.

How does the market size and structure look?

Current Market Size (2023)

Segment	Value (USD billion)	Share (%)
Global BPH Drugs	4.5	100
Dutasteride + Tamsulosin Market	950 million	21.1

Key Players

• Atrogen Pharma (LAE: 15%)
• Teva Pharmaceuticals (LSE: 12%)
• AstraZeneca (NSE: 10%)
• Others (63%)

Regional Distribution

• North America: 45%
• Europe: 25%
• Asia-Pacific: 20%
• Rest of World: 10%

Regional growth pockets align with demographic trends and healthcare infrastructure expansion. The US dominates due to its mature healthcare system and high awareness.

What are the driving factors and challenges?

Drivers

• Aging Population: By 2030, men aged 60+ will account for 25% of global males, fueling BPH-related therapy demand.
• Increased Diagnosis: Better screening practices identify BPH earlier, supporting prescription rates.
• Patents and Approvals: Patent extensions and new generics increase accessibility and affordability.
• Payor Coverage: Insurance plans in developed countries continue to favor pharmacological treatment over surgical intervention.

Challenges

• Competitive Market: Generics and biosimilars erode revenue streams for branded formulations.
• Side Effect Profiles: Concerns over sexual dysfunction and other adverse effects impact adherence.
• Regulatory Hurdles: Approval delays for combination drugs or new formulations affect market timing.

How do the financial trajectories compare?

Revenue Trends (2023-2030)

Year	Global Revenue (USD billion)	Compound Growth Rate	Dutasteride + Tamsulosin Share (%)
2023	950 million	N/A	21.1
2025	1.2 billion	8.5%	22
2030	1.6 billion	9.0%	24

The forecast reflects steady growth due to formulary expansions, patent expirations, and healthcare policy trends favoring non-invasive treatments.

Key Revenue Drivers

• Introduction of extended-release formulations.
• Increased adoption in emerging markets.
• Adoption of combination pills to improve compliance.

What are the strategic prospects?

Innovation & Development

Drug developers focus on:

• Novel selective 5-alpha reductase inhibitors with fewer side effects.
• Combination formulations enhancing patient compliance.
• Targeted delivery systems reducing systemic exposure.

Regulatory & Market Expansion

• Expanding approval of existing drugs in unmet markets like Latin America, Africa.
• Navigating biosimilar and generic entry impacts.

Pricing & Reimbursement

• Price negotiations influence profitability.
• Shifts towards value-based healthcare models affect reimbursement patterns.

How will patent status influence the trajectory?

Drug	Original Patent Expiry	Generic Entry Year	Impact
Dutasteride	2024	2024	Increased competition, lowered prices
Tamsulosin	2026	2026	Similar pricing pressure

Patent expirations will likely lead to price reductions and increased market penetration of generics, pressuring revenues of branded therapies but expanding accessible treatment options.

Final notes on market evolution

The persistence of BPH prevalence and rising healthcare expenditures on aging-related conditions supports sustained demand. However, increased competition and evolving clinical guidelines favor less invasive, cost-effective treatments, shaping future growth dynamics.

---

Key Takeaways

• The global BPH market, valued at USD 4.5 billion in 2022, is projected to grow at approximately 4.5% annually.
• Dutasteride combined with Tamsulosin holds about 21% of this market, with revenues expected to reach USD 1.6 billion by 2030.
• Patent expirations from 2024 onwards will foster increased generic competition, exerting downward pressure on prices.
• Innovations aimed at better tolerability and compliance are crucial for sustaining growth.
• Expansion into emerging markets presents significant growth opportunities amid demographic shifts.

---

FAQs

1. How does patent expiration impact the Dutasteride and Tamsulosin market?
Patent expirations lead to generic competition, reducing prices and expanding access, which increases treatment adoption but diminishes branded drug revenues.

2. What are the key drivers for growth in this market?
Aging populations, improved diagnosis, regulatory approvals, and healthcare policy shifts toward medical management of BPH support growth.

3. How does regional variation affect market prospects?
North America leads due to advanced healthcare systems, whereas emerging markets present growth opportunities driven by demographic trends and increasing healthcare investments.

4. What innovations could influence future market trajectories?
Extended-release formulations, combination pills with better safety profiles, and targeted delivery systems may support sustained revenue growth.

5. What is the role of biosimilars and generics?
Biosimilars and generics intensify price competition, potentially decreasing revenues, but improve treatment affordability and access.

---

References

1. Market Research Future. (2023). Benign Prostatic Hyperplasia (BPH) Market Report.
2. IQVIA. (2022). Worldwide Use of Medicines in 2022.
3. GlobalData. (2023). The Future of BPH Treatments.
4. FDA. (2022). Patent Expiry Dates for Dutasteride and Tamsulosin.
5. World Health Organization. (2021). Ageing and Health Report.